Ariose Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Ariose Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-238,841	Closed	-$25.7M	–	14
2016 Q4	$25.7M	Hold	238,841	–	–	8.36%	5
2016 Q3	$27.7M	Buy	+238,841	New	+$28.2M	7.56%	4
2016 Q2	–	Sell	-88,655	Closed	-$10.1M	–	12
2016 Q1	$10.1M	Sell	88,655 -158,627	-64%	-$18.6M	9.57%	4
2015 Q4	$35.2M	Buy	+247,282	New	+$28.5M	16.97%	3

Other funds holding CBPO

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

HIM

Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ariose Capital Management's CBPO Position: Q1 2017 in Review

Ariose Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2017, closing a stake of 238,841 shares — an estimated $25.7M sold.

Ariose Capital Management first reported a position in CBPO in Q4 2015 and held it in 4 quarters. The position peaked at $35.2M in Q4 2015. 136 funds tracked by Wall St. Rank hold CBPO as of Q1 2017.

Ariose Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2017 after selling out during the quarter.
Ariose Capital Management sold 238,841 China Biologic Products Holdings, Inc. shares in Q1 2017, an estimated $25.7M.
Ariose Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q4 2015 and held it in 4 quarters.
Ariose Capital Management's China Biologic Products Holdings, Inc. position peaked at $35.2M in Q4 2015.
136 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2017.

Based on Ariose Capital Management's 13F filing for Q1 2017, filed 9 May 2017.